Aryl hydrocarbon receptor activation ameliorates experimental colitis by modulating the tolerogenic dendritic and regulatory T cell formation
Cell & Bioscience volume 12, Article number: 46 (2022)
Intestinal immune dysfunction is involved in the onset of Crohn’s disease (CD). Dendritic cells (DCs), antigen-presenting cells, play a key role in the maintenance of intestinal immune homeostasis. The aryl hydrocarbon receptor (AhR) is a ligand-dependent transcription factor widely expressed in various immune cells, including DCs. Although AhR plays an important role in immune tolerance, its role in the DCs is unclear. The purpose of this study was to investigate whether the activation of AhR can induce tolerogenic DCs (tolDCs) and the differentiation of regulatory T (Treg) cells, as well as ameliorate experimental colitis.
AhR activation in the DCs resulted in a lower expression of surface markers such as CD80, CD83, CD86, and pro-inflammatory cytokine production, and higher anti-inflammatory production (IL-1β, IL-23, and IL-12) compared to the control DCs. The surface dendrites in DCs were significantly reduced following AhR activation by 6-formylindolo [3,2-b]carbazole (FICZ). Such DCs with FICZ-mediated activation of AhR, namely tolDCs, promoted Treg cell differentiation. Adoptive transfer of tolDCs to a TNBS-induced colitis mouse model significantly alleviated the severity of inflammation by improving the colon length and decreasing the disease activity index (DAI) and histopathological score. Moreover, the transferred tolDCs decreased the frequency of Th17 cells and increased the frequency of Treg cells in the spleen and mesenteric lymph nodes (MLNs) in murine colitis models.
Activation of AhR in the DCs could induce tolDCs, and the transplantation of tolDCs may help in relieving intestinal inflammation and maintaining the Th17/Treg differentiation balance. Thus, our data suggest that AhR may be a potential therapeutic target for CD.
Crohn's disease (CD) is a chronic non-specific intestinal inflammatory disease. Although its etiology and pathogenesis remain unclear, a large amount of evidence indicates that the pathological mechanisms of CD are driven by an exaggerated immune imbalance . T helper 17 (Th17) cells and regulatory T (Treg) cells are two vital lymphocyte subsets with opposing functions. While the Th17 cells have important implications in autoimmune diseases, the Treg cells control the autoimmune reactivities . Mechanically, the frequency of Th17 cells was increased, while that of Treg cells was decreased in the intestinal mucosa of CD patients . Previous studies have demonstrated that an imbalance of Th17 and Treg cells is associated with the development of CD [4, 5]. Thus, therapeutic regimens regulating the Th17/Treg cell balance may be used for the treatment of CD.
Dendritic cells (DCs) are the most important antigen-presenting cells acting as regulators of the T cell response involved in bridging the innate and adaptive immune responses. DCs recognize and process antigens, and trigger T cell-mediated immune responses. Further, they affect T cell differentiation and functions by upregulating the major histocompatibility complex (MHC) and costimulatory molecules such as CD80, CD83, and CD86, that play a crucial role in maintaining immune tolerance, including the Th17 and Treg cell balance [6, 7]. Tolerogenic dendritic cells (tolDCs) show decreased expression of costimulatory molecules and pro-inflammatory cytokines, and increased levels of anti-inflammatory cytokines, which in turn inhibit T cell priming and proliferation . It has been previously shown that growth factors, immunosuppressants, and cytokines are involved in the induction of tolDCs tolerance [9, 10]. Some transcription factors, such as nuclear factor κB (NF-κB) and aryl hydrocarbon receptor (AhR), are also involved in the differentiation of tolDCs . However, the roles of nuclear transcription factors, especially AhR, in DCs maturation and function remain largely unknown.
The role of AhR, a ligand-dependent transcription activator, in the differentiation, maturation, and function of various immune cells, has been previously investigated . AhR can be activated by various endogenous and exogenous ligands and leads to a variety of immune regulatory effects. Examples of endogenous ligands that can activate AhR include 6-for mylindolo [3,2-b]carbazole (FICZ), 2-(1'H-indole-3'-carbonyl)-thiazole-4-carboxylic acid methyl ester (ITE) and exogenous ligands include 3-methylcholanthrene (3-MC) and 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) [11, 12]. The activated AhR is translocated into the nucleus to initiate transcription of the CYP1A1 gene . Therefore, the expression levels of CYP1A may be a marker of AhR activation. AhR ligands, such as FICZ and ITE, have been shown to attenuate experimental colitis and restore the Th17 /Treg cell balance by inhibiting Th17 cell differentiation and promoting Treg cell formation [13, 14]. A previous study demonstrated that ITE could inhibit T cell-mediated immunity by acting on the DCs . Another study found that FICZ could inhibit DC-primed Th17 polarization from naïve T cells . These data suggest that AhR activation may affect the function of DCs and mediate inflammation associated with CD. However, the regulatory mechanisms of AhR on DCs remain largely unclear. Therefore, this study focuses on exploring the potential mechanisms underlying the AhR activation in DCs playing a crucial role in the regulation of auto-reactive effector T and Treg cells.
We hypothesized that AhR activation induces the tolDCs by downregulating costimulatory molecules such as CD80, CD83, CD86, and inflammatory cytokines that may prevent the pathogenic processes underlying colitis in mice. Here, we investigated the effects of AhR activation by FICZ on the maturation and functions of DCs in vitro and found that the FICZ-treated DCs exhibited tolerogenic properties, namely tolDCs. Furthermore, the tolDCs were transferred to a 2, 4, 6-trinitrobenzene sulfonic acid (TNBS)-induced murine model of colitis, and their impact on Th17/Treg cell balance was analyzed. These data show that the adoptive transfer of tolDCs alleviates TNBS- induced experimental colitis in mice, and this effect may be closely related to restoring the balance of Th17/Treg cell differentiation in vivo. Thus, our data suggest that AhR may be a potential therapeutic target for CD by inducing tolDCs.
FICZ as a ligand can effectively activate AhR in dendritic cells
To observe the AhR activation, we analyzed CYP1A1 expression (an AhR activation marker protein) by Western blotting. CYP1A1 expression was significantly upregulated by FICZ (final concentration 100 nM)- treated DCs compared to DMSO-treated DCs (Fig. 1A, B). The results indicated that AhR could be effectively activated by its ligand FICZ in the DCs.
Influence of FICZ-mediated AhR activation on the dendritic cell phenotype
Dendritic cells contain very obvious dendrite that facilitate contact with the T cells . In this study, we investigated the effects of FICZ- mediated AhR activation on the maturation of DCs in vitro. As shown in Fig. 2A, it was found that the mature DCs showed quite obvious dendrite through ordinary light microscopy. Treatment with DMSO did not change the morphology of DCs (Fig. 2B), while the DCs pretreated with 100 nM FICZ displayed small dendrites compared to the control DCs (Fig. 2C). Furthermore, scanning electron microscopy showed that massive dendrite formation on the surface of mature DCs (Fig. 2D), while the surface dendrites were significantly reduced after pretreatment with FICZ (100 nM) for 12 h. The morphology of FICZ-conditioned DCs differed from control and DMSO-treated DCs phenotypes, at least in formatting dendrite on the cell surface.
Moreover, we evaluated the surface markers such as costimulatory molecules CD80, CD83, CD86, and MHC-II of the FICZ-treated DCs using flow cytometry. As shown in Fig. 3A, the control DCs and DMSO-treated DCs expressed high levels of CD80, CD83, and CD86. FICZ significantly decreased the levels of CD80, CD83, and CD86 compared with control and DMSO (Fig. 3A, B ). FICZ had no significant effects on the MHC-II expression in the DCs. These results showed that AhR-activated DCs had low expression of costimulatory molecules.
AhR activation alters cytokine profiles of dendritic cells
To confirm whether AhR activation affected the production of cytokines in the DCs, the concentrations of pro-inflammatory (IL-1β, IL-12, and IL-23) and anti-inflammatory cytokines (IL-22, TGF-β, and IL-10) were detected by ELISA. Cytokine analysis indicated that the levels of IL-1β, IL-12, and IL-23 were significantly reduced (Fig. 4A–C). However, the levels of IL-22, TGF-β, and IL-10 secretion were significantly increased (Fig. 4D–F) in the DCs with FICZ-mediated AhR activation. In line with the ELISA results, RT-qPCR results showed that the mRNA levels of IL-1β, IL-12 and IL-23 were lower, while those of IL-22, TGF-β, and IL-10 were higher in the FICZ-treated DCs compared to the DMSO-treated or control DCs (Fig. 5A–F).
AhR-activated DCs can inhibit CD4+ T cell proliferation in vitro
To investigate the immunoregulatory capacity of the AhR-activated DCs on the T cell functions, the DCs conditioned with different factors were cocultured with allogeneic CD4+ T cells isolated from the spleen, which were stained with CFSE for three days by adding 2 μg/ml anti-CD3 in coculture medium. Using flow cytometry, T cell proliferation was examined. As shown in Fig. 6, control DCs strongly stimulated the allogeneic T cell proliferation. Slight inhibition of allogeneic antigen-stimulated T cell proliferation was observed when the DCs were treated with FICZ. These data indicate that the AhR-activated DCs may inhibit CD4+ T cell proliferation in coculture assays and reduce the number of T cells to further exhibit the tolerance characteristics.
AhR-activated DCs can promote the differentiation of Treg cells in vitro
AhR activation has been proven to prime naïve T cells to differentiate into Treg cells and inhibit Th17 cell differentiation, and further modulate the balance between the Treg and Th17 cells. However, it is still controversial whether the AhR-activated DCs influence T cell polarization. Therefore, to clarify the effects of DCs on T cell differentiation, the conditioned DCs were co-cultured with CD4+ T cells to determine whether the FICZ-treated DCs could influence Treg cell differentiation and related cytokine secretion. Flow cytometric analyses showed an increased frequency of Treg cells in the FICZ-treated DCs compared with control and DMSO-treated DCs (Fig. 7A, B). Additionally, the expression of Foxp3 protein was upregulated in the CD4+ T cells co-cultured with FICZ-treated DCs compared with control and DMSO-treated DCs (Fig. 7C, D). Further analysis revealed that the secretion levels of IL-10 in the supernatants of T cells co-cultured with FICZ-treated DCs was higher than that in the T cells cocultured with control and DMSO-treated DCs (Fig. 7E). These findings suggest that AhR activation may promote the regulation of Treg cell differentiation by DCs.
Adoptive transfer of tolDCs alleviates the severity of TNBS-induced colitis
The above results indicate that the DCs with AhR activation by FICZ may be considered as tolDCs. TolDCs exhibited tolerogenic properties in vitro. To further confirm the functions of tolDCs in vivo, we assessed whether the tolDCs played a vital role in controlling TNBS-induced colitis after disease onset. TolDCs were generated in the presence of FICZ as described above and then injected intraperitoneally (i.p.) into colitis mice 2 h after administration of TNBS. As shown in Fig. 8, compared with PBS injection, a single injection of 1 × 106 tolDCs relieved the shortening of colon length (Fig. 8A, B). Meanwhile, the adoptive transfer of tolDCs significantly decreased the DAI scores (Fig. 8C) and histology scores (Fig. 8D–E). These results indicate that tolDCs induced by the activation of AhR in vitro effectively relieve colitis, however, the underlying mechanisms are still unclear.
Transfer of tolDCs results in the restoration of balance between Treg and Th17 cells in TNBS-induced colitis
Adoptive transfer of tolDCs reduced intestinal inflammation in murine colitis, however, the underlying mechanisms are still unclear. Therefore, we examined the Th17/Treg cell balance in colitis mice injected with tolDCs. After injection with tolDCs or PBS as vehicle control, the frequency of Th17 and Treg cells in the spleen and MLNs was determined by flow cytometry. As shown in Fig. 9A, B, an increase in Th17 cells and a decrease in Treg cells were observed in the spleens of colitis mice. The population of Th17 cells in colitis mice injected with tolDCs was decreased compared with PBS-treated colitis mice. The colitis mice injected with tolDCs exhibited an increase in the population of Treg cells (Fig. 9C, D). To determine whether tolDCs restore the imbalance of Th17/Treg cells in MLNs, we detected the proportion of Th17 and Treg cells in MLNs by using flow cytometry. The results indicated that the proportion of Th17 cells in the MLNs of colitis mice was increased. After colitis mice were adoptively transferred with tolDCs, the proportion of Th17 cells in MLNs decreased. Interestingly, the proportion of Treg cells in the MLNs of colitis mice was higher than that in the control group, which showed no obvious intestinal inflammation. The increased proportion of Treg cells in the MLNs of mice with colitis might be a compensatory response to control severe injury. However, cells isolated from MLNs in colitis mice injected with tolDCs were detected the level of Th17 and Treg cells, and the percentage of Treg cells was significantly increased compared with PBS-treated colitis mice (Fig. 9E–H). These data suggest that tolDC injection in colitis mice may alleviate intestinal inflammation by restoring the differentiation balance of Th17/Treg cells.
Accumulating evidence indicates that the function of DCs is dependent on their state of maturation, and that the function of mature DCs is immunogenic, whereas immature or semi-mature DCs are less immunogenic or may even exhibit tolerogenic capability [18, 19]. Therefore, immunogenic DCs play a crucial role in the priming and polarization of CD4+ T cells into effector T helper (Th), which participate in regulating immune responses [20, 21]. TolDCs drive T cells to differentiate into Treg cells and regulate peripheral tolerance [21, 22]. CD28 is expressed in T cells and can bind with costimulatory molecules in DCs to trigger T cell activation . TolDCs show low expression of co-stimulatory molecules such as CD80 and CD86. Due to their lack of sufficient co-stimulatory molecular signaling pathways mediated by CD80 and CD86, this kind of DCs triggered effector T cells to be disabled or even apoptosis, prime T cells differentiate into Tregs, and then play an important role in immune suppression . The differentiation of Treg cells relies on the DC-secret IL-10 and TGF-β. To date, numerous drugs and factors have been used to induce and maintain DCs tolerogenic by enhancing their capacity to promote activation of Treg cells [25, 26]. Strategies for repairing T cell immune homeostasis are expected to be translated into clinical application in the treatment of inflammatory bowel disease (IBD). Previous studies have demonstrated that AhR activation induces functional Tregs, which suppress the development of experimental transplant and autoimmune diseases [27, 28]. However, others have reported that FICZ directly promotes Th17 cell production by AhR activation in vitro . In this study, the DCs were found to have reduced proinflammatory cytokines and increased anti-inflammation cytokines and subsequently enhanced the differentiation of Treg cells.
In accordance with previous studies, our results indicated that DCs treated with endogenous ligands FICZ exhibited decreased dendrite and downregulated expression of costimulatory molecules such as CD80, CD86, and CD83, inhibited pro-inflammatory cytokines such as IL-β, IL-12, and IL-23, which might further contribute to Th17 cell differentiation. The levels of IL-10 in the supernatants of FICZ-treated DCs increased. In turn, AhR-activated DCs converted T cells to Treg cells under co-culture conditions in a DC-T cell co-culture system. However, when co-cultured with AhR-activated DCs, the proliferation of CD4+ T cells was only slightly suppressed (from 18.9 to 16.1%), which may not be the main mechanism of tolerance induction. Furthermore, we found that the potent anti-inflammation of AhR activation may be involved in the maturation and function of DCs. These data are similar to those by Kayama  and Aoki  which reported that AhR activation could regulate the maturation and function of DCs an induce tolDCs by promoting Treg cells resolution and function.
The role of DCs in initiating autoimmune diseases and transplant rejection, especially in IBD, which characterize intestinal inflammation. Many efforts have been made to investigate the possible attractive avenue for clinical applications of tolDCs by using animal models of experimental colitis. In this study, we used FICZ to increase the activity of AhR in DCs and produce tolerogenic DCs. Previous studies have investigated the transfer of other kinds of tolDCs induced by immunomodulators to colitis mice significantly reduced the severity of colon inflammation [30,31,32]. In humans, ex vivo tolDC injection has been applied to clinical type 1 diabetes  and multiple sclerosis . The clinical trial in patients with CD is on the way. In this study, to determine the tolerogenic DCs induced by FICZ treatment on the suppression of inflammation in TNBS-induced colitis, we performed adoptive transfer of the tolDCs to colitis mice. The results showed that the tolDCs induced by the AhR ligand FICZ prevented colon inflammation by regulating the Th17/Treg balance in colitis models.
Our data highlight the importance of crosstalk between tolerogenic DCs and T cells in colitis. This study has some limitations. First, in this study, DCs were cocultured with T cells to detect their differentiation, but DCs and T cells were not cultured in separate chambers to further verify the importance of costimulatory molecules. In addition, intestinal cytokine secretion in mice was not detected after DC injection. Finally, the levels of infiltrating Th17 cells and Treg cells in suffering colons were not detected. Therefore, it cannot be directly proved that adoptive transfer of tolDCs regulates the balance of Th17 and Treg in the colon. In the future, we will further confirm the molecular mechanisms related to the induction and function maintenance of DCs by AhR activation and provide a theoretical basis for its potential clinical application.
In vitro, BMDCs were treated with a kind of AhR ligand, FICZ, and the treated DCs were differentiated to tolerogenic properties by characterization of low expression of costimulatory molecules, low secretion of pro-inflammatory cytokines, and high anti-inflammatory cytokines. Furthermore, the induced tolerogenic DCs effectively enhanced Treg cell differentiation, and the adoptive transfer of tolDCs inhibited immune responses by balancing Th17/Treg cells in a mouse model of colitis. Therefore, our findings may provide new targets for the induction of immune tolerance and control of intestinal inflammation in patients with CD. In conclusion, the possibility of generating tolerogenic DCs by AhR ligand opens a new therapeutic avenue for the treatment of CD.
Materials and methods
Male specific pathogen-free (SPF) C57BL/6 mice (6–8 weeks old, 18–20 g weight, n = 10/each group) were purchased from the Laboratory Center of Nanjing University (Jiangsu, China). All the mice were kept in the Nanjing Medical University Animal Care Facilities and were raised in clean cages under SPF environment with a 12 h light–dark cycle. The mice were given one-week period of adaptation prior to the experiment. All experimental procedures were approved by the Experimental Animal Ethics Committee of Nanjing Medical University (Ethics number: IACUC-1901005).
Culturing of DCs derived from bone marrow progenitors
As previously described , bone marrow DCs (BMDCs) were generated from the murine bone marrow (BM). Briefly, the BM cells were flushed with RPMI1640 medium (Gibco) and passed through a 40 μm nylon mesh to remove pieces of bone and debris as well as the erythrocytes. Further, the BM cells were cultured in RPMI 1640 medium containing 1% penicillin–streptomycin (NCM Biotech, C125C8) supplemented with 10% fetal bovine serum (FBS, Biological Industries, 04-001-0A), 20 ng/ml granulocyte–macrophage colony-stimulating factor (GM-CSF, 315–03), and 10 ng/ml murine recombinant c (IL-4, Peprotech, 214–14). The medium containing fresh cytokines was added to the cells every three days. On Day-6, the BMDCs were purified using magnetic anti-CD11c beads (Stem cell, 18780A). The purified DCs were treated with 100 nM FICZ or dimethyl sulfoxide (DMSO) (< 0.1%) as vehicle control for 12 h and then activated with 100 ng/ml lipopolysaccharide (LPS, Sigma-Aldrich) for another 24 h.
Scanning electron microscopy
The treated (with DMSO or FICZ) and untreated (control) DCs were fixed in 2.5% glutaraldehyde, dehydrated in ethanol, and critical point dried including fixation and dehydration, transferring from pure acetone to the intermediate solution isoamyl acetate, then replacing isoamyl acetate with liquid carbon dioxide for the samples. The samples were then mounted on aluminum stubs and coated with gold by a sputtering device (Emitech, Ashford, GB). The final cell specimens were observed using a JSM 6700F scanning electron microscope (Jeol, Peabody, MA) at 2.5 kV.
T cell proliferation experiment
The CD4+ T cells were isolated from the spleen of male C57BL/6 mice (6–8 weeks, 18–20 g) by using a T cell isolation kit (BD Biosciences, Catalog: 551539) and labeled with carboxyfluorescein diacetate succinimidyl ester (CFSE, 2.5 μM; Invitrogen, Catalog: C34570). The labeled CD4+ T cells were washed twice with RPMI 1640 complete medium and subsequently co-cultured with The treated (with DMSO or FICZ) and untreated (control) DCs. DCs and CD4+ T cells were co-cultured at a 1:10 ratio for 72 h (stimulator cells: responder cells = 1:10) by adding 2 μg/ml anti-CD3. The proliferation of CD4+ T cells was then analyzed by flow cytometry.
The DCs were stained with fluorescent-labeled antibodies against CD11c, CD80, CD83, CD86, MHC-II, or isotype-matched controls (BioLegend, San Diego, CA, USA). Briefly, the cells were incubated with the antibodies for 30 min at 4 ˚C and subsequently washed with PBS containing 1% FBS. The mature markers CD11c, CD80, CD83, CD86, MHC-II of DCs were analyzed. For Th17 cell analysis, the cells were stimulated with phorbol 12-myristate 13-acetate (PMA, 50 ng/mL, Sigma, P8139) and ionomycin (1 μM, Sigma, Catalog: I3909) in the presence of GolgiPlug (BD, 555029) for 4 h to detect IL-17A. For intracellular staining, the cell surface staining was performed by incubating the cells with FITC-conjugated anti-CD4 (Invitrogen, 11-0042-82) and APC-conjugated anti-CD25 (Invitrogen, 17-0251-81). Further, the cells were fixed, permeabilized, and stained with PE-conjugated anti-Foxp3 (Invitrogen, 12-5773-82) or PE-conjugated anti-IL-17A (Invitrogen, 12-7177-81) using a Transcription Factor Fixation/Permeabilization Kit (eBioscience, 00-5123). All data were analyzed using FlowJo software (Treestar, Ashland, OR, USA) .
T cell differentiation
CD4+ T cells were purified from the spleens and lymph nodes of male C57BL/c mice using a CD4+ T cell isolation kit (BD Biosciences, 551539) by positive selection according to the manufacturer’s instructions. The cells were then stimulated with 2 μg/mL anti-CD3 (eBioscience, 16-0031-85) and cocultured with 2 × 104 DCs for five days. To induce Treg polarization, IL-2 (100 U/ml) and TGF-β1 (5 ng/ml) were added to the culture medium , and the cells cultured under the polarization conditions were harvested and analyzed by flow cytometry.
Enzyme-linked immunosorbent assay (ELISA)
Cytokines (IL-1β, IL-12, IL-23, IL-22, TGF-β, and IL-10) in culture medium were determined by enzyme-linked immunosorbent assay (ELISA) using specific kits according according to the manufacturer's instructions. All the ELISA kits were purchase from Neobioscience Technology Co., Ltd., China.
The cells were washed twice with PBS and then lysed in RIPA Lysis Buffer (Beyotime, China) supplemented with a protease inhibitor cocktail (Medchem Express, Nanjing, China). The protein concentrations were determined using an Enhanced BCA Protein Assay Kit (Beyotime, China). Quantitative protein samples (30 μg/lane) were separated on 10% sodium dodecyl sulfate–polyacrylamide gels and transferred to PVDF membranes. After blocking with 5% nonfat milk, the membranes were incubated overnight with anti-CYP1A1 antibody (Proteintech Group, Inc., 1:1000, 13241-1-AP), anti-FOXP3 antibody (Abcam, 1:1000, ab54501), and anti-GAPDH antibody (Bioworld Technology, Inc., 1:10000, AP0063) at 4˚C. Following incubation with horseradish peroxidase-conjugated goat anti‑rabbit antibodies (Bioworld Technology, Inc., 1:10000, BS13278), protein blotting was visualized using an Enhanced Chemiluminescence (Life Technologies, Carlsbad, USA). Data ware analyzed using Image-Lab 6.0.1 software (Bio-Rad).
Real-time quantitative polymerase chain reaction (RT-qPCR)
RNA was isolated using TRIzol® reagent (Life Technology) and purified using a gDNA wiper kit. cDNA was synthesized by reverse transcription from 1 µg RNA using a HiScript® II Q RT SuperMix, and RT-qPCR was performed on an ABI 7300 Real-Time PCR System (Thermo Scientific) via ChamQ Universal SYBR qPCR Master Mix. All reagents were obtained from Vazyme Biotech Co., Ltd. The primers for the related genes were designed and synthesized by Qingke Biotechnology Co., Ltd. In the present study, the following primers were used (mouse): IL-1β forward 5-AAGGGGACATTAGGCAGCAC-3 and reverse 5-ATGAAAGACCTCAGTGCGGG-3; IL-12 forward 5- GGGACCAGGCCCTATTATGC -3 and reverse 5- TTGCATCCATTTGTGTGGCG -3; IL-23 forward 5-AAATAATGTGCCCCGTATCCAG-3 and reverse 5-GAAGATGTCAGAGTCAAGCAGGTG-3; IL-22 forward 5-ATGAGTTTTTCCCTTATGGGGAC-3 and reverse 5- GCTGGAAGTTGGACACCTCAA-3; TGF-β forward 5- CAATTCCTGGCGTTACCTTG-3 and reverse 5-AGCCCTGTATTCCGTCTCCT-3; IL-10 forward 5-GCTCTTACTGACTGGCATGAG-3′ and reverse 5-CGCAGCTCTAGGAGCATGTG-3; GAPDH forward: 5-AGGTCGGTGTGAACGGATTTG-3 and reverse 5-TGTAGACCATGTAGTTGAGGTCA-3′. The relative gene expression was determined using 2−△△CT, and the housekeeping gene GAPDH was used as a reference control.
Induction of experimental colitis by TNBS
Experimental colitis was induced using TNBS according to a previously described protocol [38, 39]. Briefly, C57BL/c mice were fasted, with free access to 5% glucose water, for 24 h before administering the enema, and were then randomly assigned to five groups (n = 10/per group). Mice were lightly anesthetized by inhalation of low-dose ether. TNBS was diluted to 50% with an equal volume of 100% ethanol. In the TNBS group, each mouse was treated with 100 μl 50% TNBS by slighting inserting a catheter to colon about 4 cm from the anus and was maintained to a head-down position for about 1 min to prevent drug solution from flowing out. In the vehicle-treated group, each mouse was infused with an equal volume of 50% ethanol. The disease activity index (DAI) was used to evaluate colonic damage including weight loss, stool consistency, and bloody stool, as described previously . Histological scores of colon HE staining were calculated using a method described in previous studies [41, 42].
Adoptive transfer experiment
The BMDCs were pretreated with 100 nM FICZ and then subsequently activated by LPS to induce tolDCs in vitro as mentioned above. Then, the tolDCs were collected and washed three times with sterile PBS to remove any remaining FICZ. To assess the effect and mechanism of tolDCs on colitis, 1 × 106 tolDCs or control DCs were injected intraperitoneally to colitis mice. The vehicle mouse was injected intraperitoneally with an equal volume of sterile PBS.
All data are expressed as mean ± standard deviation (SD) and analyzed using SPSS 25.0 software (IBM Company, Armonk, NY). The differences among groups were analyzed using one-way analysis of variance (ANOVA) and Bonferroni correction. All graphs were drawn using Graphpad software 8.0 (GraphPad Inc., San Diego, CA). A P-value lower than 0.05 was considered statistically significant.
The original data supporting this research conclusion will be availability from the corresponding author.
Inflammatory bowel disease
Aryl hydrocarbon receptor
Disease activity index
T helper 17 cells
Regulatory T cells
Major histocompatibility complex
Nuclear factor κB
2- (1'H-indole-3'-carbonyl)-thiazole-4-carboxylic acid methyl ester
6-Formylindolo [3,2-b] carbazole
Aryl hydrocarbon receptor nuclear translocator
2,4,6-Trinitrobenzenesulfonic acid H&E hematoxylin–eosin
Bone marrow derived dendritic cells FBS fetal bovine serum
Enzyme-linked immunosorbent assay RT-qPCR real time quantitative PCR
Granulocyte–macrophage colony-stimulating factor IL-4 interleukin (IL)-4
Carboxyfluorescein diacetate succinimidyl ester
Phorbol 12-myristate 13-acetate
Mesenteric lymph nodes
Guan Q. A comprehensive review and update on the pathogenesis of inflammatory bowel disease. J Immunol Res. 2019. https://doi.org/10.1155/2019/7247238.
Afzali B, Lombardi G, Lechler RI, et al. The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease. Clin Exp Immunol. 2007;148(1):32–46.
Cho J, Kim S, Yang DH, et al. Mucosal immunity related to FOXP3(+) regulatory T Cells, Th17 cells and cytokines in pediatric inflammatory bowel disease. J Korean Med Sci. 2018;33(52):e336.
Geremia A, Biancheri P, Allan P, Corazza GR, et al. Innate and adaptive immunity in inflammatory bowel disease. Autoimmun Rev. 2018;13(1):3–10.
Globig AM, Hennecke N, Martin B, et al. Comprehensive intestinal T helper cell profiling reveals specific accumulation of IFN-gamma+IL-17+coproducing CD4+ T cells in active inflammatory bowel disease. Inflamm Bowel Dis. 2014;20(12):2321–9.
Rescigno M, Di Sabatino A. Dendritic cells in intestinal homeostasis and disease. J Clin Invest. 2009;119(9):2441–50.
Yamazaki S, Iyoda T, Tarbell K, Olson K, et al. Direct expansion of functional CD25+ CD4+ regulatory T cells by antigen-processing dendritic cells. J Exp Med. 2009;198(2):235–47.
Amodio G, Gregori S. Human tolerogenic DC-10: perspectives for clinical applications. Transplant Res. 2012;1(1):14.
Ricchetti G, Williams LM, Foxwell BM. Heme oxygenase 1 expression induced by IL-10 requires STAT-3 and phosphoinositol-3 kinase and is inhibited by lipopolysaccharide. J Leukoc Biol. 2004;76(3):719–26.
Kryczanowsky F, Raker V, Graulich E, et al. IL-10-modulated human dendritic cells for clinical use: identification of a stable and migratory subset with improved tolerogenic activity. J Immunol. 2004;197(9):3607–17.
Iberg CA, Hawiger D. Natural and induced tolerogenic dendritic cells. J Immunol. 2020;204(4):733–44.
Veldhoen M, Hirota K, Westendorf AM, et al. The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins. Nature. 2020;453(7191):106–9.
Aoki R, Aoki-Yoshida A, Suzuki C, et al. Indole-3-pyruvic acid, an Aryl hydrocarbon receptor activator, suppresses experimental colitis in mice. J Immunol. 2020;201(12):3683–93.
Lv Q, Wang K, Qiao SM, et al. Norisoboldine, a natural aryl hydrocarbon receptor agonist, alleviates TNBS-induced colitis in mice, by inhibiting the activation of NLRP3 inflammasome. Chin J Nat Med. 2020;16(3):161–74.
Abron JD, Singh NP, Mishra MK, et al. An endogenous aryl hydrocarbon receptor ligand, ITE, induces regulatory T cells and ameliorates experimental colitis. Am J Physiol Gastrointest Liver Physiol. 2018;315(2):G220–30.
Wang C, Ye Z, Kijlstra A, Zhou Y, et al. Activation of the aryl hydrocarbon receptor affects activation and function of human monocyte-derived dendritic cells. Clin Exp Immunol. 2018;177(2):521–30.
Tanaka H, Demeure CE, Rubio M, et al. Human monocyte-derived dendritic cells induce naive T cell differentiation into T helper cell type 2 (Th2) or Th1/Th2 effectors. Role of stimulator/responder ratio. J Exp Med. 2010;192(3):405–12.
O’Neill DW, Adams S, Bhardwaj N. Manipulating dendritic cell biology for the active immunotherapy of cancer. Blood. 2010;104(8):2235–46.
Patente TA, Pelgrom LR, Everts B. Dendritic cells are what they eat: how their metabolism shapes T helper cell polarization. Curr Opin Immunol. 2010;58:16–23.
Kapsenberg ML. Dendritic-cell control of pathogen-driven T-cell polarization. Nat Rev Immunol. 2003;3(12):984–93.
Domogalla MP, Rostan P, Raker VK, et al. Tolerance through education: how tolerogenic dendritic cells shape immunity. Front Immunol. 2003;8:1764.
Rodrigues CP, Ferreira AC, Pinho MP, et al. Tolerogenic IDO(+) dendritic cells are induced by PD-1-expressing mast cells. Front Immunol. 2003;7:9.
Harding FA, McArthur JG, Gross JA, et al. CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature. 1992;356(6370):607–9.
Qureshi OS, Zheng Y, Nakamura K, et al. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science. 1992;332(6029):600–3.
Tarbell KV, Yamazaki S, Steinman RM. The interactions of dendritic cells with antigen-specific, regulatory T cells that suppress autoimmunity. Semin Immunol. 2006;18(2):93–102.
Lin CL, Huang HM, Hsieh CL, et al. Jagged1-expressing adenovirus-infected dendritic cells induce expansion of Foxp3(+) regulatory T cells and alleviate T helper type 2-mediated allergic asthma in mice. Immunology. 2006;156(2):199–212.
Quintana FJ, Basso AS, Iglesias AH, et al. Control of T(reg) and T(H)17 cell differentiation by the aryl hydrocarbon receptor. Nature. 2008;453(7191):65–7.
Apetoh L, Quintana FJ, Pot C, Joller N, et al. The aryl hydrocarbon receptor interacts with c-Maf to promote the differentiation of type 1 regulatory T cells induced by IL-27. Nat Immunol. 2008;11(9):854–61.
Kayama H, Takeda K. Regulation of intestinal homeostasis by innate and adaptive immunity. Int Immunol. 2012;24(11):673–80.
Aoki R, Aoki-Yoshida A, Suzuki C, et al. Indole-3-pyruvic acid, an Aryl hydrocarbon receptor activator, suppresses experimental colitis in mice. J Immunol. 2018;201(12):3683–93.
Delgado M, Gonzalez-Rey E, Ganea D. The neuropeptide vasoactive intestinal peptide generates tolerogenic dendritic cells. J Immunol. 2005;175(11):7311–24.
Gonzalez-Rey E, Delgado M. Therapeutic treatment of experimental colitis with regulatory dendritic cells generated with vasoactive intestinal peptide. Gastroenterology. 2006;131(6):1799–811.
Giannoukakis N, Phillips B, Finegold D, et al. Phase I (safety) study of autologous tolerogenic dendritic cells in type 1 diabetic patients. Diabetes Care. 2011;34(9):2026–32.
Willekens B, Presas-Rodriguez S, Mansilla MJ, et al. Tolerogenic dendritic cell-based treatment for multiple sclerosis (MS): a harmonised study protocol for two phase I clinical trials comparing intradermal and intranodal cell administration. BMJ Open. 2019;9(9):e030309.
Rogers PB, Schwartz EH. Generation of large numbers of myeloid progenitors and dendritic cell precursors from murine bone marrow using a novel cell sorting strategy. J Vis Exp. 2018. https://doi.org/10.3791/57365.
Dong Z, Chen Y, Peng Y, et al. Concurrent CCR7 overexpression and RelB knockdown in immature dendritic cells induces immune tolerance and improves skin-graft survival in a murine model. Cell Physiol Biochem. 2018;42(2):455–68.
Hang S, Paik D, Yao L, et al. Bile acid metabolites control TH17 and Treg cell differentiation. Nature. 2019;576(7785):143–8.
Gu P, Zhu L, Liu Y, et al. Protective effects of paeoniflorin on TNBS-induced ulcerative colitis through inhibiting NF-kappaB pathway and apoptosis in mice. Int Immunopharmacol. 2019;50:152–60.
Iraporda C, Romanin DE, Bengoa AA, et al. Local treatment with lactate prevents intestinal inflammation in the TNBS-induced colitis model. Front Immunol. 2019;7:651.
Guo J, Yang LJ, Sun M, et al. Inhibiting microRNA-7 expression exhibited a protective effect on intestinal mucosal injury in tnbs-induced inflammatory bowel disease animal model. Inflammation. 2019;42(6):2267–77.
Schmidt N, Gonzalez E, Visekruna A, et al. Targeting the proteasome: partial inhibition of the proteasome by bortezomib or deletion of the immunosubunit LMP7 attenuates experimental colitis. Gut. 2010;59(7):896–906.
Pouillart PR, Depeint F, Abdelnour A, et al. Nutriose, a prebiotic low-digestible carbohydrate, stimulates gut mucosal immunity and prevents TNBS-induced colitis in piglets. Inflamm Bowel Dis. 2010;16(5):783–94.
We thank Xinyu Xu for providing technical support about flow cytometry. In addition, we are also grateful for the equipment provided by the public platform laboratory to ensure the progress of this research. We would like to thank Editage (www.editage.com) for English language editing.
This work was supported by National Natural Science Foundation of China (81770553 and 82070568), and Postgraduate Research & Practice Innovation Program of Jiangsu Province (JX10213640).
Ethics approval and consent to participate
The animal study was approved by the Experimental Animal Ethics Committee of Nanjing Medical University (Ethics number: IACUC-1901005).
Consent for publication
All authors read and approved the paper.
The authors declare that they have no conflict of interest.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Cui, X., Ye, Z., Wang, D. et al. Aryl hydrocarbon receptor activation ameliorates experimental colitis by modulating the tolerogenic dendritic and regulatory T cell formation. Cell Biosci 12, 46 (2022). https://doi.org/10.1186/s13578-022-00780-z